NEW RESEARCH DEMONSTRATES AQTUAL’S PLATFORM IDENTIFIES SYNOVIAL SIGNATURES IN PATIENTS WITH RHEUMATOID ARTHRITIS USING A ROUTINE BLOOD TEST

– Study findings presented during ACR Convergence podium presentation HAYWARD, Calif., Nov. 15, 2023 /PRNewswire/ — Aqtual, a precision medicine company using a novel cell-free DNA platform to develop products for chronic diseases and oncology, announced research today that demonstrates…

Click here to view original post